# Psychiatric Pharmacogenomics Gene Panel

## Core Pharmacokinetic Genes

| Gene | Function | Relevance |
|------|----------|-----------|
| **CYP2D6** | Major drug-metabolizing enzyme | Metabolizes ~40% of antipsychotics including risperidone, aripiprazole, brexpiprazole, and partially olanzapine |
| **CYP2C19** | Drug-metabolizing enzyme | Metabolizes many antidepressants including escitalopram, citalopram, and sertraline |
| **CYP1A2** | Drug-metabolizing enzyme | Primary metabolizer for olanzapine and clozapine |
| **CYP3A4** | Drug-metabolizing enzyme | Metabolizes risperidone, aripiprazole, brexpiprazole, and many other psychiatric medications |
| **CYP3A5** | Drug-metabolizing enzyme | Works with CYP3A4 in metabolizing several psychiatric medications |
| **CYP2B6** | Drug-metabolizing enzyme | Metabolizes bupropion and partially other antidepressants |
| **CYP2C9** | Drug-metabolizing enzyme | Metabolizes some antidepressants and valproic acid |
| **CES1** | Carboxylesterase 1 | Metabolizes methylphenidate and other ester-containing drugs |
| **EPHX1** | Epoxide hydrolase | Metabolizes carbamazepine epoxide and other drug metabolites |

## Transporter Genes

| Gene | Function | Relevance |
|------|----------|-----------|
| **ABCB1** (P-glycoprotein, MDR1) | Drug transporter | Affects brain penetration and transport of risperidone, aripiprazole, and many antidepressants |
| **ABCG2** | Drug transporter | Affects transport and distribution of some psychiatric medications |
| **SLC6A4** (Serotonin transporter) | Neurotransmitter transporter | Target for SSRIs, affects response to antidepressants |
| **SLCO1B1** | Organic anion transporting polypeptide | Influences transport of various medications including statins (relevant for psychiatric medications with metabolic side effects) |

## Pharmacodynamic Genes

| Gene | Function | Relevance |
|------|----------|-----------|
| **HTR2A** | Serotonin receptor | Target for many antipsychotics and antidepressants |
| **HTR2C** | Serotonin receptor | Associated with antipsychotic-induced weight gain |
| **DRD2** | Dopamine receptor | Primary target for all antipsychotics |
| **HLA-A** | Human leukocyte antigen | Associated with serious adverse reactions to carbamazepine |
| **HLA-B** | Human leukocyte antigen | HLA-B*15:02 associated with serious skin reactions to carbamazepine |
| **MC4R** | Melanocortin receptor | Associated with antipsychotic-induced weight gain |
| **OPRM1** | Opioid receptor mu 1 | Affects response to opioid analgesics and some psychiatric medications |
| **CHRNA3** | Cholinergic receptor nicotinic alpha 3 | Associated with nicotine dependence and smoking behavior |
| **GRIK1** | Glutamate receptor, ionotropic kainate 1 | Associated with response to topiramate and other anticonvulsants |
| **GRIK4** | Glutamate receptor, ionotropic kainate 4 | Associated with antidepressant response |
| **SCN1A** | Sodium voltage-gated channel alpha subunit 1 | Target for mood stabilizers and anticonvulsants |

## Phase II Metabolism Genes

| Gene | Function | Relevance |
|------|----------|-----------|
| **UGT1A4** | Glucuronidation enzyme | Metabolizes olanzapine and lamotrigine |
| **UGT2B10** | Glucuronidation enzyme | Involved in metabolism of some psychiatric medications |
| **UGT2B15** | Glucuronidation enzyme | Metabolizes benzodiazepines and other psychotropic medications |

## Other Relevant Genes

| Gene | Function | Relevance |
|------|----------|-----------|
| **COMT** | Catechol-O-methyltransferase | Affects dopamine metabolism |
| **MTHFR** | Methylenetetrahydrofolate reductase | Folate metabolism; linked to depression risk and treatment response |
| **ADRA2A** | Alpha-2A adrenergic receptor | Target for some antidepressants |
| **BDNF** | Brain-derived neurotrophic factor | Associated with antidepressant response |
| **FKBP5** | FK506 binding protein | Involved in stress response and antidepressant action |
| **ANK3** | Ankyrin 3 | Associated with bipolar disorder susceptibility and lithium response |
| **CACNA1C** | Calcium voltage-gated channel | Associated with bipolar disorder and response to calcium channel blockers |
| **ANKK1** | Ankyrin repeat and kinase domain containing 1 | Located near DRD2, associated with addiction risk and antipsychotic response |

## Sources

1. Korošec Hudnik, L., Blagus, T., Redenšek Trampuž, S., Dolžan, V., Bon, J., & Pjevac, M. (2024). Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics. Frontiers in Psychiatry, 15, 1363051. PMID: 38566958

2. Squassina, A., Paribello, P., Pinna, M., Contu, M., Pisanu, C., Congiu, D., et al. (2025). A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 e CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID: 39971121

3. Malik, S., Verma, P., Ruaño, G., Al Siaghy, A., Dilawar, A., Bishop, J.R., et al. (2024). Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications. Journal of Child and Adolescent Psychopharmacology. PMID: 38377525

4. Goh, S.E., Jamuar, S.S., Chua, S.E., Yeo, D.C.K., Goh, J.H.Y., Chin, C.H., et al. (2024). Pharmacogenomics in psychiatry: Practice recommendations from an Asian perspective. Annals of the Academy of Medicine, Singapore. PMID: 39748172

5. Ragia, G., Pallikarou, M., Manolopoulou, Y., Vorvolakos, T., & Manolopoulos, V.G. (2024). Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation. Pharmacogenomics. PMID: 38884939 